Combinatorial RNA interference as a gene therapy strategy for HIV-1 infection by Spanevello, Francesca et al.
Combinatorial RNA interference as a gene therapy
strategy for HIV-1 infection
Francesca Spanevello, Arianna Calistri, Claudia Del Vecchio, Barbara
Mantelli, Saverio Parisi, Giorgio Palu`, Marina Cavazzana-Calvo, Cristina
Parolin
To cite this version:
Francesca Spanevello, Arianna Calistri, Claudia Del Vecchio, Barbara Mantelli, Saverio Parisi,
et al.. Combinatorial RNA interference as a gene therapy strategy for HIV-1 infection. Retro-
virology, BioMed Central, 2013, 10 (Suppl 1), pp.P85. <inserm-00868811>
HAL Id: inserm-00868811
http://www.hal.inserm.fr/inserm-00868811
Submitted on 2 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
POSTER PRESENTATION Open Access
Combinatorial RNA interference as a gene
therapy strategy for HIV-1 infection
Francesca Spanevello1*, Arianna Calistri1, Claudia Del Vecchio1, Barbara Mantelli1, Saverio G Parisi1, Giorgio Palù1,
Marina Cavazzana-Calvo2,3, Cristina Parolin4
From Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts
Cambridge, UK. 16-18 September 2013
Background
RNA interference (RNAi) is a mechanism of gene-
suppression with potential gene therapy applications
against chronic viral diseases. Combinatorial RNAi
approaches are required to account for viral variability in
treating HIV-1 infection, as single short hairpin RNAs
(shRNAs) are rapidly rendered ineffective by resistant
strains. Although promising, these approaches need to be
optimized in terms of target selection, hairpin design and
promoter choice in order to provide a highly effective
anti-HIV-1 therapeutic strategy.
Materials and methods
Validated small interfering RNAs (siRNAs) with targets
within cellular CCR5 gene and HIV-1 tat/rev and vif
sequences were inserted into a lentiviral vector under the
control of either the U6, the 7SK or the H1 human poly-
merase III promoters, alone or in different combinations.
Alternatively, the siRNAs were simultaneously expressed
as an extended shRNA (e-shRNA) under the control of
each selected promoter. Silencing efficiencies of the differ-
ent vectors were compared by means of the luciferase
knockdown assay. siRNAs antiviral activity and cytotoxicity
were assessed both in cell lines and in human primary
cells, including macrophages and CD4+ T lymphocytes.
Results
Experiments performed on single shRNA-expressing
vectors indicated a specific silencing activity of the selected
sequences, with the siRNAs targeting the CCR5 and the
tat/rev genes leading up to 90% reporter gene knockdown.
Activities of the U6 and H1 promoters were similar and
superior to that of the 7SK, irrespective of the expressed
siRNA. Furthermore, siRNA-CCR5 induced a marked cell
surface CCR5 downregulation in transduced primary
macrophages. When different siRNA transcriptional units
were combined within a single vector, the silencing activity
of each siRNA was not affected by its relative position in
transfection experiments. On the other hand, differences
were observed in transduced cells challenged with wild
type HIV-1. As an alternative combinatorial approach, we
designed an extended short hairpin RNA giving rise to
three different siRNAs targeting CCR5, tat/rev and vif,
under the control of either the U6, the 7SK or the H1
promoter. The obtained results showed that the silencing
activity is strictly dependent on the used promoter, with
the H1 being the most active, both in terms of target gene
knockdown and inhibition of viral replication. In addition,
the biosafety of human cell lines and primary cells expres-
sing multiple siRNAs was evaluated and transduction at
high multiplicity of infection turned out to affect endogen-
ous microRNA processing.
Conclusions
This study confirms that combinatorial RNAi is a feasible
approach to counteract HIV-1 replication, highlighting
some important strengths and pitfalls of different plat-
forms used for multiple siRNAs delivery. The data provide
valuable insights for the design and application of reliable
combinatorial RNAi that, once shown to be safe and effec-
tive in vivo, may be next in line for clinical testing.
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